Welcome to Insider Trades Daily, glad you're here! Every day, more than 500,000 investors use this newsletter to track insider buying and selling across major public companies. It’s a simple way to see what the people closest to the business are doing with their own money. Before we start sending your daily updates, there’s just one quick thing left to do. Please confirm your subscription using the link below. Click Here to Confirm Your Subscription to Insider Trades Daily It takes a few seconds and helps make sure your newsletter shows up where it belongs, your inbox, not a spam folder. Once you’re confirmed, we’ll take it from there and deliver clear, no-nonsense insider trading insights straight to you. Start Receiving Insider Information The InsiderTrades.com Team P.S. If there's anything we can do to improve your experience, please let us know by replying to this email.
More Reading from MarketBeat.com
Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in FocusSubmitted by Jessica Mitacek. Posted: 5/8/2026. 
Key Points
- Following a settled legal dispute with Novo Nordisk, HIMS has transitioned from selling compounded weight-loss drugs to offering brand-name Wegovy and Ozempic.
- While the deal was finalized in March, investors are eager to see if this pivot will boost the top line or if the financial impact likely won’t be seen until Q2.
- Despite its recent rally, the stock remains highly volatile with short interest exceeding 35%.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
Healthcare stocks have struggled in 2026. With a year-to-date (YTD) loss of about 6%, the sector has been the worst performer among all 11 S&P 500 sectors this year. That weakness has shown up in the YTD losses of some of Big Pharma’s biggest names, but it has also hurt mid-cap stocks like telehealth platform Hims & Hers Health (NYSE: HIMS), which has fallen by more than 23% in 2026.
When the SpaceX IPO launches, most retail investors will be locked out. The banks, funds, and insiders get in early - while everyone else waits on the sidelines.
But one small infrastructure supplier - a critical piece Musk can't scale the Colossus network without - is still trading well under institutional radar. A new briefing reveals the name and ticker at no cost. Get the SpaceX infrastructure stock name and ticker here
One day after a major announcement from the U.S. Food & Drug Administration (FDA) sent shares of HIMS up nearly 4%, the stock gave back those gains on Thursday, falling nearly 5% as traders locked in profits. Still, that wasn’t enough to derail the stock’s recent rally. HIMS has gained nearly 32% over the past month and around 77% since its 52-week low on Feb. 27. As the company prepares to report Q1 2026 earnings on May 11, here’s what investors should watch. Is the Novo Nordisk Partnership Already Paying Off?Following a well-publicized legal dispute earlier this year with Denmark-based Novo Nordisk (NYSE: NVO)—the eighth-largest publicly traded pharmaceutical company in the world, with a market cap of more than $204 billion—it’s been smooth sailing for Hims & Hers. Since Novo Nordisk dropped its patent infringement lawsuit on March 9, HIMS has been on a tear. Not only did the Danish company abandon its case, but it also reached a deal that allows Hims & Hers to sell Novo Nordisk’s brand-name Wegovy and Ozempic through its direct-to-consumer and virtual medical services platform. As part of that deal, Hims & Hers agreed to stop advertising its compounded GLP-1 products, a move that may prove prescient given the FDA’s announcement that it is proposing semaglutide, tirzepatide, and liraglutide be excluded from its 503B bulks list. Wall Street will be watching to see how that deal has affected Hims & Hers’ top line. Although the strategic shift was announced on March 9, Novo Nordisk’s GLP-1 products were not available for sale through the online platform until March 26. Since the first quarter closed on March 31, those gross sales may not show up on Hims & Hers’ income statement until Q2. Will Hims & Hers Continue to Show Subscriber Growth?The market will also be looking for confirmation that Hims & Hers’ total subscribers are holding above 2.5 million, if not continuing to grow. That milestone was reached near the end of 2025 and marked a more than 16% increase from the 2.2 million subscribers the company had at the end of 2024. That growth appears to be sustainable after Hims & Hers ended 2023 with 1.5 million subscribers. More important than the raw subscriber count, though, is the fact that the telehealth company generates 90% of its recurring revenue from its customer base. Approximately 82% of its users remain on the platform for more than three months, and if Hims & Hers can show that trend is holding, it should support full-year guidance. Meanwhile, analysts are expecting earnings per share (EPS) of around three to four cents, which would mark an estimated 90% year-over-year decline. That may already be priced in, given the stock’s YTD performance, but a miss could accelerate selling. The same goes for quarterly revenue, which consensus forecasts place in the range of $616 million to $619 million. Wall Street is already bracing for a “reset quarter” after revenue growth slowed from nearly 111% in Q1 2025 to less than 29% in Q4, so any upside surprise could fuel another leg of the current rally. Analysts Are Taking a Wait-and-See ApproachDespite an average 12-month price target of nearly $32, which implies potential upside of around 24%, Wall Street remains cautious on the stock. Of the 17 analysts currently covering HIMS, four rate it a Buy, 12 rate it a Hold, and just one rates it a Sell. Overall, the stock carries a consensus Hold rating. Institutional ownership of nearly 64% falls within the typical range for mid-cap companies. Outflows of $1.62 billion have nearly matched inflows of $1.8 billion over the past 12 months, after selling accelerated in Q4 2025. But that trend reversed in Q1, with institutional selling 88% lower than institutional buying. With a high beta of 2.43, the stock’s volatility continues to make it a target for bears. Concerningly, more than 35% of the float—or nearly 70 million shares of the almost 228 million shares outstanding—is currently shorted. Still, strong earnings could shift sentiment and move the stock closer to the consensus analyst price target. Shareholders and prospective investors should mark their calendars for Monday, May 11, when Hims & Hers Health reports Q1 2026 results. |
No comments:
Post a Comment